Selective 5-HT2A Modulators Avoiding Dopamine D2 Side Effects
Solution Overview
Problem
Current treatments for 5-HT2A serotonin receptor-associated disorders often come with motor-related side effects due to interaction with other receptors like the human dopamine D2 receptor, necessitating the development of atypical anti-psychotic therapies that do not interfere with these receptors.
Innovation Solution
Development of specific compounds, as described in Formula (Ia), that modulate the activity of the 5-HT2A serotonin receptor, providing therapeutic benefits for disorders such as schizophrenia, depression, and anxiety without the motor-related side effects by stabilizing the receptor in an active state through ligand-independent means.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If typical anti-psychotic compounds are used to treat 5-HT2A serotonin receptor-associated disorders, then therapeutic effects are achieved, but motor-related side effects occur due to interaction with dopamine D2 receptor
Solution Approach 1:
The invention extracts and eliminates the harmful interaction with dopamine D2 receptor while preserving the therapeutic effect on 5-HT2A serotonin receptor. The atypical anti-psychotic compounds are designed to selectively target 5-HT2A receptor without binding to or interfering with dopamine D2 receptor, thereby removing the source of motor-related side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The invention applies local quality by creating compounds with selective receptor affinity. The molecular structure is optimized to have high specificity for 5-HT2A serotonin receptor binding site while lacking affinity for dopamine D2 receptor binding site. This localized selectivity ensures therapeutic action occurs only at the intended target without affecting other receptors.
2Object-affected harmful factors
If compounds are designed to selectively target 5-HT2A receptor without interacting with dopamine D2 receptor, then motor-related side effects are reduced, but therapeutic efficacy may be compromised
Solution Approach 1:
The invention employs parameter changes by modifying molecular parameters such as binding affinity, selectivity ratio, and receptor interaction characteristics. The atypical anti-psychotic compounds are designed with optimized parameters including high 5-HT2A receptor binding affinity combined with low or negligible dopamine D2 receptor affinity, creating a favorable selectivity profile that maintains therapeutic efficacy while minimizing side effects.
Data Source
AI summary
The present invention pertains to certain compounds of Formula (Ia),and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infraction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.



